Rituxan + BEAM and Auto Stem Cell Transplant for High Risk Lymphoma or Hodgkin's Disease

Not Applicable

Completed

Conditions: Hodgkin's Disease
Lymphoma

Interventions: Drug: Melphalan
Drug: Ara-C
Drug: VP-16
Drug: BCNU
Drug: Rituxan
Drug: Stem Cells

Registration Number: NCT01702961

Lead Sponsor: Baylor College of Medicine

Brief Summary: High-dose chemotherapy followed by autologous (the patient's own) peripheral blood (circulating blood) stem cell (cells that divide to form white cells, red cells and cells that help clot) transplantation is a conventional treatment for patients with lymphoma (cancer of lymph glands) and Hodgkin's disease (cancer of lymph glands) after first relapse (recurrence of disease). For patients who did not have a complete response after traditional chemotherapy, the chance is high that the tumor will return even after high-dose chemotherapy. To improve the response and decrease the chance of relapse, doctors have used rituximab, an antibody that kills lymphoma cells, both before and after transplantation. These doctors have reported that more patients had control of the tumor for an extended period of time using rituximab with high-dose chemotherapy with autologous stem cell transplantation. How widely this is applicable is not known.

The purpose of this clinical research trial is to confirm that there is a good control of tumor in patients with lymphoma or Hodgkin's disease treated with rituximab and conventional stem cell transplantation.

Detailed Description: Subjects will receive the chemotherapy through a plastic tube (catheter) placed into a vein under the collarbone. The antibody rituximab is given on the day of admission. The subject will also start a six-day course of chemotherapy at that time. The chemotherapy will consist of the following drugs: BCNU, etoposide also called VP-16, Ara-C also called cytosine arabinoside, and melphalan. BCNU is given on the first day, Ara-C and VP-16 on the second, third, fourth and fifth days, and melphalan on the sixth day. The infusion of blood stem cells is given through the catheter the day after the last dose of chemotherapy. This is called Day 0. A week later the subject will receive shots under the skin of Neupogen to help the stem cells grow quickly. Three additional doses of rituximab are given weekly starting 2 weeks later. If the subject recovers and is discharged from the hospital before getting all the doses of rituximab, they can receive the remainder in clinic.

Patients will remain in the hospital for approximately 3-4 weeks, and in the Houston area for about 30 days from the infusion of the donor cells. The patient will have blood, urine, bone marrow, and x-ray examinations performed as necessary to monitor the results of treatment. They will have blood tests daily while hospitalized.

As an outpatient, the patient will be monitored to make sure their immune system (system in the body that helps protect the body and fights bacterial, viral and fungal infections) is recovering, and the patient may require additional infusions of immunoglobulins (infection-fighting blood proteins) until the blood protein levels are safe. The patient will also be taking antibiotic pills for about 6 months to prevent infections. They will have x-rays and other diagnostic tests (PET scans) every 6-12 months during the next 5 years to make sure the tumor stays under control.

Recruitment & Eligibility

Status: COMPLETED

Sex: All

Target Recruitment: 75

Inclusion Criteria

Patients with biopsy-proven, relapsed, or refractory CD20+ lymphoma, or HD.
At least 2e6 CD34+/kg autologous PBSC stored. If patients are non-mobilizers, then at least 2e8 TNC/kg autologous marrow should be stored.
Patient is not pregnant.
Zubrod performance status less than or equal to 2.
Life expectancy is not severely limited by concomitant illness.
Left ventricular ejection fraction greater than or equal to 50%.
No uncontrolled arrhythmias or symptomatic cardiac disease.
FEV1, FVC and DLCO greater than or equal to 50%.
No symptomatic pulmonary disease.
Serum creatinine less than or equal to 1.5 mg/dL.
Serum bilirubin less than or equal to 2X upper limit of normal, SGPT less than or equal to 3X upper limit of normal.
No evidence of chronic active hepatitis or cirrhosis.
No effusion or ascites greater than or equal to 1L prior to drainage.
HIV negative.
Patient or guardian able to sign informed consent.
Patients of any age may be enrolled on this protocol.

Exclusion Criteria

Anyone not meeting the above criteria.

Study & Design

Study Type: INTERVENTIONAL

Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
BEAM+R: Autologous Stem Cell Transplant	BCNU	Ara-C, VP-16, BCNU, Melphalan, Rituxan and Stem Cells
BEAM+R: Autologous Stem Cell Transplant	Melphalan	Ara-C, VP-16, BCNU, Melphalan, Rituxan and Stem Cells
BEAM+R: Autologous Stem Cell Transplant	Rituxan	Ara-C, VP-16, BCNU, Melphalan, Rituxan and Stem Cells
BEAM+R: Autologous Stem Cell Transplant	Stem Cells	Ara-C, VP-16, BCNU, Melphalan, Rituxan and Stem Cells
BEAM+R: Autologous Stem Cell Transplant	VP-16	Ara-C, VP-16, BCNU, Melphalan, Rituxan and Stem Cells
BEAM+R: Autologous Stem Cell Transplant	Ara-C	Ara-C, VP-16, BCNU, Melphalan, Rituxan and Stem Cells

Primary Outcome Measures

Name	Time	Method
Disease-free Survival	12 months post-transplant	Disease-free survival at 12 months post-transplant in patients with Hodgkin's disease or non-Hodgkin's lymphomas

Secondary Outcome Measures

Name	Time	Method
Median Days to Neutrophil Engraftment	30 days post-transplant	Neutrophil engraftment was recorded as the first day that absolute neutrophil counts (ANC) exceeds 0.5 X 10\^9/L for three consecutive readings.
Number of Participants With Overall Best Response Achieved After Transplantation	3 months post-transplant	Response was summarized as complete remission (CR): disappearance of all evidence of disease; partial remission (PR): regression of measurable disease (\>=50% decrease in sum of the product of the diameters (SPD) of up to six of the largest dominant nodes or nodal masses) and no new sites; stable disease (SD): failure to attain CR/PR/PD; relapsed disease or progressive disease (PD): any new lesion or increase by \>= 50% of previously involved sites from nadir.